
In a U-turn on its previous guidance NICE is now recommending that the £330,000 rare disease drug Soliris should be …

The UK healthcare system is at risk of failing to adopt new, personalised medicines and must be willing to pay …

NICE is to be responsible next year for assessing high cost drugs for people with rare medical conditions as part …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

